Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.50 |
| ▸ | KDR | P35968 | 11/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.50 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 15/20 | 0.47 |
| ▸ | LCK | P06239 | 8/20 | 0.47 |
| ▸ | YES1 | P07947 | 8/20 | 0.47 |
| ▸ | FYN | P06241 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.46 |
| ▸ | CASK | O14936 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143687 | 0.90 | SRC (0.49) | PDGFRBKDRFGFR1TLK2SRC | |
| SCHEMBL146649 | 0.87 | PDGFRB (0.41) | PDGFRBKDRFGFR1TLK2SRC | |
| SCHEMBL143213 | 0.86 | SRC (0.48) | PDGFRBKDRFGFR1TLK2SRC | |
| SCHEMBL144979 | 0.85 | KDR (0.71) | PDGFRBKDRFGFR1TLK2SRC | |
| SCHEMBL6515665 | 0.82 | FLT1 (0.47) | PDGFRBKDRFGFR1TLK2SRC | |
| SCHEMBL144114 | 0.78 | AURKA (0.44) | PDGFRBKDRFGFR1SRCLCK | |
| SCHEMBL142619 | 0.77 | KDR (0.69) | PDGFRBKDRFGFR1TLK2SRC | |
| SCHEMBL2116627 | 0.76 | KDR (0.61) | PDGFRBKDRFGFR1TLK2EGFR | |
| SCHEMBL13755246 | 0.76 | KDR (0.61) | PDGFRBKDRFGFR1TLK2EGFR | |
| SCHEMBL31672554 | 0.76 | KDR (0.61) | PDGFRBKDRFGFR1TLK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | PDGFRB 467/4885KDR 1077/4885FGFR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.